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and 49% were male. Users with a VTE history (12%) had a longer duration of anti-
coagulant use versus those without a VTE history. Of those with a VTE history,
15% used anticoagulants for2 months. The average/median duration of therapy
was 15/2, 2.3/2, 19/12, 41/30 days for all users, users of unfractionated heparin
(UFH), low-molecular-weight heparin (LMWH), and vitamin K antagonist (VKA),
respectively. Anticoagulant use was highest in colorectal cancer patients (40%) and
lowest in bladder cancer patients (9%). Most commonly prescribed anticoagulants
were UFH (75%), VKA (20%), and LMWH (8%). CONCLUSIONS: Approximately 1/3 of
cancer patients used anticoagulants around chemotherapy. Anticoagulant use var-
ies by tumor type ranging between 9%-40%. Heparin was the most commonly
prescribed agent and VKA had the longest therapy duration.
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OBJECTIVES: To compare the potential cost of long-acting treatments with lan-
reotide vs octreotide for GEP-NET using patient treatment characteristics from the
PHARMO Record Linkage System (RLS) in the Netherlands. METHODS: A cost min-
imization model was used to compare lifetime costs of the SSAs. Data for patients
receiving outpatient dispensing of long-acting SSA (2003–2010) were selected from
PHARMO RLS. GEP-NET patients were identified by relevant hospital discharge
diagnoses. Dosing and injection intervals were assessed during the first stable
treatment period (i.e., the period of SSA dispensings with constant dosage and little
variation in injection intervals). RESULTS: A total of 82 octreotide LAR users and 10
lanreotide Autogel users were identified. Stable treatment was observed in 54/82
(66%) octreotide and 8/10 (80%) lanreotide users; median (IQR) duration of the first
stable phase was 3 (2-6) and 5 (4-6) months, respectively. Among stable users, most
received medium doses (5/8 (63%) vs 35/54 (65%)). One (2%) octreotide user and
none of the lanreotide users received low dose. High doses were received by 18/54
(33%) on octreotide vs 3/8 (38%) on lanreotide. Stratified by week, 9/54 (17%) oc-
treotide users received injections every 3 weeks or more frequently, 36/54 (67%)
every 4 weeks, 7/54 (13%) every 5 weeks and 2/54 (3%) every 6 weeks or less fre-
quently; 7/8 (88%) lanreotide users received injections every 4 weeks and 1/54 (13%)
every 6 weeks or less frequently. Mean injection intervals were 278 days for
octreotide and 3110 days for lanreotide. This resulted in an average GEP-NET
patient cost 7% less with lanreotide than octreotide based on the cost minimization
model. CONCLUSIONS: This analysis suggests long-acting lanreotide use may re-
duce costs compared with long-acting octreotide. The driver of cost savings was
the longer injection interval with lanreotide during stable treatment for GEP-NET.
The nature of the disease implies low patient numbers.
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There is limited data available on health care resource utilization (HRU) associated
with metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVES: To as-
sess HRU in mCRPC patients during treatment. METHODS: Observational, retro-
spective, year-long study conducted in 47 centres specialised in prostate cancer
(PC) in 6 countries: Belgium, France, Germany, Sweden, the Netherlands, and the
UK. Patients with confirmed mCRPC diagnosis and documented disease progres-
sion were eligible. HRU data over the previous 2 years (or from mCRPC diagnosis
onwards if 2 years) were collected from patients’ medical records by physicians.
Interim results on 212 patients, of 699 included patients, are presented below.
RESULTS: Mean age was 73.0 years. Mean time since PC diagnosis was 6.6 years. At
diagnosis, 35.7% of patients had metastases and 79.7% had Gleason score 7. At
inclusion, 33.8% of patients had never been treated with any prior chemotherapy,
35.3% had been treated with chemotherapy previously and 30.8% were currently
undergoing chemotherapy. Mean time since failure on androgen-deprivation ther-
apy was respectively 1.2, 1.6 and 1.5 years. Chemotherapy consisted principally of
docetaxel (82.0%). Patients without prior chemotherapy presented lower rates of PC
surgery (5.9%) than patients with past (11.3%) or ongoing chemotherapy (12.9%).
Palliative radiotherapy was more frequent in patients with past chemotherapy
(28.2%) than in patients without prior chemotherapy (19.1%) or with ongoing che-
motherapy (14.5%). Higher hospitalisation rates were observed in patients with
past (43.7%) or ongoing chemotherapy (43.5%) than in patients without prior che-
motherapy (23.5%). Mean hospitalisation durations were roughly equivalent (re-
spectively 6.1, 6.8 and 5.7 days). Emergency room visits were more frequent in
patients with ongoing chemotherapy (14.5%) than in patients without prior che-
motherapy (7.4%) or with past chemotherapy (9.9%). CONCLUSIONS: This study
provides HRU information, which will be implemented into a cost analysis in order
to highlight the determinants of the economic burden of mCRPC patients.
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OBJECTIVES: Chemotherapy-induced FN can result in reduced chemotherapy de-
livery, unplanned hospitalizations, increased mortality risk, and substantial HCU.
Little is known about FN-related HCU among cancer patients in Dutch clinical
practice. METHODS: Data from incident adult BC and NHL-patients from 1998–
2007 were obtained from the PHARMO Record Linkage System, including phar-
macy, hospital, and lab data. Eligible patients had12 months medical history and
received chemotherapy within 6 months after cancer diagnosis. Patients develop-
ing FN within 6 months after first chemotherapy (“FN-patients”) were matched 1:2
on gender, birth-year, and chemotherapy-regimen to patients without FN (“non-
FN-patients”). HCU-data (hospitalizations, medical procedures, drug use [number
dispensed]) was tallied from entry date (date of FN or matched date for non-FN-
patients) for up to 3 months. Statistics are descriptive with crude odds ratios (OR).
RESULTS: As a result, 80/1033 (8%) BC-patients developed FN. 95/486 (20%) NHL-
patients developed FN. Eighty and 89 FN-patients were matched, respectively.
More FN-patients than non-FN-patients were hospitalized in the first month after
entry date (BC: 73% vs 14% [OR23.0; 95%CI:(8.3-63.7)]; NHL: 78% vs 33% [OR7.6;
95%CI:(3.9-15.1)]). These differences were mainly due to FN-related hospitaliza-
tions (BC: 55% vs 1%; NHL: 47% vs 4%). FN-patients also had a longer mean length of
stay per all-cause hospitalization (BC: 4.6 vs 1.9 days; NHL: 10.1 vs 3.0 days). Mean
number of total drugs dispensed in the first month was higher in FN-patients than
in non-FN-patients (BC: 5.8 vs 3.1; NHL: 8.5 vs 3.6), as was use of anti-infectious
agents (BC: 99% vs 11%; NHL: 96% vs 20%) and other non-chemotherapy drugs. More
FN-patients than non-FN-patients had medical procedures (BC: 14% vs 3%; NHL:
13% vs 8%). HCU-differences between FN-patients and non-FN-patients were
maintained after 3 months. CONCLUSIONS: HCU in BC and NHL-patients with FN
in the Netherlands is substantial. Reduction of FN may improve quality of life and
save resources.
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OBJECTIVES: There has been concern that new oncology medicines may not be
accessible to patients due to the requirement to demonstrate cost-effectiveness in
order to gain public reimbursement. In Australia, Public Summary Documents
(PSDs) reporting on the Pharmaceutical Benefits Advisory Committee’s (PBAC) de-
cision making relating to government reimbursement of medicines have been pub-
lished since July 2005. A review of PSDs reporting on oncology drugs which pre-
sented cost-effectiveness analyses was undertaken to identify the success factors
for achieving a positive recommendation. METHODS: Data related to history, clin-
ical outcomes, cost-effectiveness and recommendations for oncology drugs from
published PSDs between July 2005 and November 2011 were extracted and
reviewed. RESULTS: Eighty-one PSDs were reviewed of which 51 were first, 18
second and 12 subsequent submissions. The PBAC recommended 26 for listing on
the Australian Pharmaceutical Benefits Scheme (PBS). Of the first, second and sub-
sequent submissions, 29%, 33% and 42% received a positive recommendation re-
spectively. Of those that reported a AU$/QALY, the range was: below $15k; 0% of
instances, 15-45k; 67%, 45-75k; 33%, 75-105k; 0% and above 105k; 0%. The findings
were generally similar when AU$/LYG was reported, however one product was
approved with AU$/LYG greater than $105k under the “rule of rescue”. Of the prod-
ucts approved with AU$/QALY or LYG greater than $45k factors that were noted
included high clinical need, risk sharing agreement and further price negotiation.
CONCLUSIONS:Cost per QALY above $45k is acceptable in conjunction with factors
such as clinical need and robust evidence. Nevertheless, further price negotiation
may be required to gain reimbursement on the Australian PBS.
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OBJECTIVES: The NICE reference case requires that health-related quality of life
(HRQoL) data should be reported directly from patients, preferably using the EQ-5D
(2008 Methods guide, updating recommendations in 2004 Methods guide). The ob-
jective of this review was to evaluate the source of utility data in oncology apprais-
als conducted since the 2004 Methods guide up to the present day. METHODS:
Completed NICE appraisals of oncology drugs conducted since the 2004 methods
guide were reviewed. Data including model structure, utility data sources, and
values reported for the main health states were extracted. RESULTS: Fifty-one
completed NICE appraisals were reviewed. This included 61 separate evaluations
accounting for MTAs. 43% provided utilities based on EQ-5D data from patients
with the relevant disease for at least one of the main health states in the model.
However, there was considerable variation within this – only 34% included EQ-5D
data for all main health states, and in only 28% were utilities precisely matched to
the indication sought (same therapy line etc. . .). Only 20% included EQ-5D data
from patients actually receiving the drug being appraised. In total, 28% of submis-
sions provided data from patients on the drug under consideration (either through
EQ-5D or another measure). Although most appraisals were for advanced/meta-
static cancer, utility values reported were reasonably high - the majority of apprais-
als reported utilities for the initial health state (typically stable disease) of between
0.65 – 0.85. CONCLUSIONS: This review highlights the paucity of available utility
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data in oncology – the majority of appraisals did not consider utility data in line
with the NICE reference case. Even where the reference case was adhered to, often
data did not come from trials of the intervention being appraised. This will intro-
duce obvious uncertainty when evaluating the impact of the intervention on
QALYs.
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OBJECTIVES: In January 2009, the National Institute for Health and Clinical Excel-
lence (NICE) introduced the end-of-life criteria, which give more weight to QALYs
for life-extending, end-of-life interventions. Since then, a number of therapies
have been recommended by NICE under these criteria that may not have been
approved otherwise. However, it has not been ascertained whether this increase in
access to important cancer treatments has been mirrored in Scotland. The aim of
this study was to review the advice of the Scottish Medicines Consortium (SMC) on
the end-of-life interventions approved by NICE. METHODS: All NICE single tech-
nology appraisals on cancer treatments issued between December 2008 and June
2012 were reviewed. All interventions that were approved under the end-of-life
regulations were identified, and NICE’s acceptance was compared with the advice
given by the SMC. RESULTS: In total, 9 cancer interventions were approved under
the end-of-life criteria, all of which had also been submitted for similar indications
to the SMC. Only 2 of these therapies were accepted for full use by the SMC, both
after resubmissions including patient access schemes (PAS). Of the remaining 7
interventions, 3 were not recommended by the SMC, and in 2 of these cases this
was stated to be due to a lack of sufficiently robust economic evidence. The other 4
treatments were accepted for restricted use; 2 of these after resubmissions and 1
with a PAS. CONCLUSIONS: Of the 9 cancer interventions approved by NICE under
the end-of-life criteria, 3 were not recommended by the SMC, and 4 out of the
remaining 6 were only accepted after resubmissions. The introduction of the end-
of-life criteria by NICE may therefore have contributed to differences in access to
cancer interventions within the UK, a trend potentially further exacerbated by the
introduction of the Cancer Drugs Fund in England.
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OBJECTIVES: Tobacco smoking is the leading cause of early death and morbidity in
the Western World. The causal association between smoking and a range of can-
cers, heart disease and chronic obstructive lung disease is well-established. Nu-
merous publications show that increased tobacco prices leads to lower tobacco
consumption. The aim of this study is to show the aggregated price elasticity be-
tween sale of cigarettes and price on cigarettes in Denmark from 1978 to 2010.
METHODS: Data on the price of cigarettes is from Statistics Denmark table PRIS1
(1978-2000) and PRIS6 (2000-2010). The price index of cigarettes was deflated with
the consumer price index. Data on sale of cigarettes in Denmark is from Statistics
Denmark table ALKO4. Price elasticity was estimated with OLS regression. Data
were analyzed in SAS version 9.2. RESULTS: The real price of cigarettes has de-
creased in Denmark between 1978 and 2010. The estimated crude aggregated price
elasticity for cigarettes in Denmark from 1978-2010 -0.4 (p 0.015) which is in line
with results for other countries. CONCLUSIONS: The price on cigarettes is a tool to
regulate the consumption of cigarettes. A tool that have not yet been used in
Denmark where there have been a decrease in the real price of cigarettes. Studies
have shown that especially youth and lower income groups have high price elas-
ticity on tobacco goods. These groups can be hard to reach with other prevention
measures. An increase in tobacco taxation especially if done across Europe and
with increased police effort to stop smuggling and contraband cigarettes could be
a way to lower the population’s tobacco consumption.
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OBJECTIVES: To estimate trends in medical Computed Tomography (CT) use and
associated radiation exposure in Canada, we assessed the annual effective dose
from CT scans, and estimated the potential related cancer risk. METHODS: CT
examinations in Canada have increased over 400% since 1994 to approximately
4.4M scans annually in 2010. Despite the medical benefits, there is concern regard-
ing radiation-related cancer risk. We developed a mathematical model to estimate
the annual effective dose, and potential cancer risk in Canada from CT, by year,
age, sex, and type of CT exams. RESULTS: From 1994 to 2010, CT examinations
increased from 38 to 127 per 1,000 population (7.8% annual increase). Abdominal /
pelvic CT had the largest annual increase at 10.3%, a five-fold increase in scans,
whereas brain and spine scans grew two-fold. The average effective dose per CT
scan went up from 6.1 mSv to 7.1 mSv. The mean per capita effective dose in-
creased four-fold, at 8.5% annually, from 0.23 mSv to 0.90 mSv. In 2010, males and
females ages 65, had annual doses of 3.2 mSv and 2.5 mSv per capita, respectively.
In the base-case scenario, the potential incidence of radiation induced cancer was
estimated at 2.9 cases per 10,000 population. Extensive sensitivity analyses have
been performed. The risk of cancer in males 65 was 2.9 times greater than for
males 40-64. The risk in females 65was 2.2 times greater than for females 40-64.
The risk in males 65 was 29% higher than in females 65. CONCLUSIONS: For
many patients, the potential benefits of CT scans outweigh foreseeable carcino-
genic risk. Substantial increases in CT technology utilization and recent studies
linking low-dose ionizing radiation to cancer suggest it would be sound policy to
lower patient exposure to ionizing radiation and informing patients about the
potential risk.
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OBJECTIVES: Eribulin mesylate (Eisai, Japan) was approved by the European Com-
mission in March 2011 for the treatment of locally advanced or metastatic breast
cancer in patients who had progressed after at least two chemotherapeutic regi-
mens. The approval, which was granted through the centralised process, was
based on results of the Phase III EMBRACE Trial which demonstrated a statistically
significant increase in overall survival (OS) for the eribulin study arm versus the
treatment of physician’s choice (TPC) arm. This study aims to discern how reim-
bursement bodies in key European countries have assessed the drug, with its high
price, since its approval. METHODS: We reviewed the reimbursement guidance on
eribulin in key European markets and determined whether the decisions were
positive or negative, and how those decisions reflect different weightings of clinical
versus economic (or other) evidence in the assessments. RESULTS: German au-
thorities concluded that eribulin had additional benefits over existing therapies,
despite an initial negative decision by IQWiG, allowing Eisai to enter pricing nego-
tiations. The Italian Medicines Agency and France’s Transparency Commission
both positively recommended the drug for approval in January 2012 and October
2011 respectively. The UK’s NICE as well as the Scottish Medicines Consortium
(SMC) rejected eribulin in April 2012 and October 2011 respectively.CONCLUSIONS:
Despite eribulin’s centralised approval process, reimbursement decisions on the
drug have varied widely among European countries. Although there has been
movement towards greater alignment between European reimbursement agencies
regarding funding decisions, this still has not come to pass as the Eurozone’s fi-
nancial crises threaten to further stymie reimbursement decision harmonisation.
The positive assessments highlight the clinical efficacy of the drug and strength of
the clinical evidence, though questions remain over the economic case.
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OBJECTIVES: To characterize final NICE recommendations for anti-cancer agents
indicated for 15 selected cancers, over time. METHODS: The analysis was based on
a review of 58 drug-indication assessments, representing solid tumor and hema-
tological cancers, published on NICE’s website (January 2001–March 2012). From
each assessment, we extracted the manufacturer’s initial submission base case
incremental cost-effectiveness ratio (ICER), inclusion of a patient access scheme
(PAS), application of end-of-life (EOL) consideration, and final NICE decision.
RESULTS: Average manufacturer base case ICER increased over time, and the per-
centage of drugs not recommended increased from 0% in 2001 to 54% in 2011.
Across all years, NICE recommended 62% (36/58) drug-indication combinations.
Among these, 14% (5/36) included a PAS only, 11% (4/36) satisfied EOL criteria only,
and 22% (8/36) included both a PAS and satisfied EOL criteria. Seventy-two percent
(26/36) had a manufacturer base case ICER  £30,000, of which 27% (7/26) included
a PAS with the initial submission, resulting in a base case ICER  £30,000. Of the 10
recommended drug-indication combinations with a manufacturer base case ICER
 £30,000, 5 included a PAS with the initial manufacturer submission and another
3 satisfied EOL criteria only. Additionally, 11 drug-indication combinations in-
cluded a PAS with initial manufacturer submission, of which 4 satisfied EOL crite-
ria, but none were recommended. CONCLUSIONS: Over time, manufacturer base
case ICERs  £30,000 have become more common, although NICE is more likely to
recommend cancer drugs if the base case ICER is £30,000. Drugs with a base case
ICER  £30,000 are recommended, typically, when the manufacturer and NICE
reach an agreement to reduce cost of treatment through a PAS or when the cancer
drug satisfies EOL criteria. Nevertheless, inclusion of a PAS with the initial manu-
facturer submission does not guarantee a positive recommendation.
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OBJECTIVES: Evaluate how NICE applies the small patient population criterion
(EOL-SPP) of its End-of-Life (EOL) supplemental advice and confirm whether or not
it applies this criterion to currently licensed indications only. METHODS: NICE’s
website was searched for cancer drug single technology assessments (STA) from
January 2009 to May 2012. Only those assessments where EOL considerations ap-
plied were selected for further evaluation. Each STA was evaluated on how NICE
used the EOL-SPP criterion. RESULTS: We identified 25 STAs for which EOL advice
was given for 29 anti-cancer agents, including guidance on one final appraisal
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